Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid.

Menzinger, Sébastien; Kaya, Gürkan; Schmidt, Enno; Fontao, Lionel; Laffitte, Emmanuel

Menzinger, Sébastien; Kaya, Gürkan; Schmidt, Enno; Fontao, Lionel; Laffitte, Emmanuel.

Affiliation

Menzinger S; Department of Dermatology, University Hospital of Geneva, CH-1205 Geneva, Switzerland. sebastien.menzinger@hcuge.ch.

Acta Derm Venereol ; 98(2): 284-286, 2018 Feb 07.

Article in En | MEDLINE | ID: mdl-29136264

Subject(s)

Immunologic Factors/therapeutic use; Omalizumab/therapeutic use; Pemphigoid, Bullous/drug therapy; Skin/drug effects; Aged; Autoantibodies/blood; Autoantigens/immunology; Biomarkers/blood; Biopsy; Dystonin/immunology; Female; Fluorescent Antibody Technique; Humans; Immunoglobulin E/blood; Non-Fibrillar Collagens/immunology; Pemphigoid, Bullous/blood; Pemphigoid, Bullous/diagnosis; Pemphigoid, Bullous/immunology; Remission Induction; Severity of Illness Index; Skin/immunology; Skin/pathology; Treatment Outcome; Collagen Type XVII

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin / Pemphigoid, Bullous / Omalizumab / Immunologic Factors Type of study: Diagnostic_studies Limits: Aged / Female / Humans Language: En Journal: Acta Derm Venereol Year: 2018 Type: Article Affiliation country: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google